Table 1.

Anti-AXL agents currently in preclinical or clinical development

CompanyCompoundTarget(s)IndicationClinical status
ServierS49076 (kinase inhibitor)MET, AXL, FGFR1/2/3Advanced solid tumorsPhase I 2013-003079-37
Mirati Therapeutics Inc.MGCD516 (kinase inhibitor)MET, AXL, and members of the VEGFR, PDGFR, DDR2, TRK, and Eph familiesAdvanced solid tumorsPhase I NCT02219711
Mirati Therapeutics Inc.MGCD265 (kinase inhibitor)MET/AXLAdvanced malignanciesPhase I NTC00697632
Betta Pharmaceuticals Co., LtdBPI-9016M (kinase inhibitor)MET/AXLAdvanced solid tumorsPhase I NCT02478866
BerGenBio ASBGB324 (R428; kinase inhibitor)AXLNSCLC and AMLPhase I/IINCT02488408NCT02424617
Tolero Pharmaceuticals and Astex PharmaceuticalsTP-0903 (kinase inhibitor)AXLPancreatic cancer, lung cancerPreclinical

Abbreviations: AML, acute myelogenous leukemia; DDR, discoidin domain receptor; Eph, ephrin; FGFR, fibroblast growth factor receptor; PDGFR, platelet-derived growth factor receptor; TRK, tropomyosin receptor kinase.